新辅助治疗是胰腺癌切除后临床相关漏 (ISGPS等级B/C) 的危险因素:回顾性队列研究

Carl-Stephan Leonhardt1,2, Sakher Shraim1, Karim Abdelazim1

  • 1Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.

Annals of surgical oncology
|November 22, 2025
PubMed
概括

新辅助疗法 (NAT) 增加了胰腺癌手术后临床相关漏的风险. 这一发现强调了为接受NAT和胰腺管腺癌 (PDAC) 切除的患者提供量身定制的术后护理的必要性.